The wave of financing in the pharmaceutical field is still continuing, and the financing amount exceeding 100 million yuan has become the norm

Since the beginning of this year, the domestic pharmaceutical and medical and health fields are still very hot
.
According to data, from January to August, a total of 1,026 financing events occurred in the national biomedical industry, with a cumulative amount of 89.
174 billion yuan
.
In addition, since the third quarter of this year, a number of medical equipment-related companies have also completed a new round of financing; According to the published amount, the financing scale ranges
from tens of millions of yuan to billions of yuan.
Recently, a number of pharmaceutical companies have announced the completion of financing
.
Among them, it is worth noting that the financing amount of more than 100 million yuan has obviously become the norm
.
Pushkang Biotech has completed more than 100 million C+ round of financing Recently, Zhejiang Pushkang Biotechnology Co.
, Ltd.
(hereinafter referred to as Pushkang Biotechnology) completed more than 100 million yuan C+ round of financing
.
This round of financing was led by October Capital, followed by Shijie Venture Capital, Changan Huitong, etc.
, and the old shareholder Yinglian Health continued to increase its weight
.
It is understood that Pushkang Biologics, founded in 2014, is a centrifugal microfluidics platform enterprise, adhering to the concept of "making health testing within reach", focusing on the field of critical and chronic disease management testing, and developing microfluidic technology products
that can cover multiple scenarios and departments.
This round of financing will further accelerate the pipeline expansion of Pushkang centrifugal microfluidics platform products around critical illness + chronic disease management, accelerate overseas sales layout, and the landing of immunobiochemical coagulation integrated machine, the leading product under research, will bring innovative power
to the POCT market.
Shinwoo Medical Completes Nearly 100 Million Yuan Series B Financing A few days ago, Hangzhou Shenwok Medical Technology Co.
, Ltd.
, an innovative company in the field of neuromodulation in China, announced (hereinafter referred to as "Shenwok Medical") that it has successfully completed nearly 100 million yuan of Series B financing
.
This round of financing was led by SDIC Venture Capital, and the old shareholder Boyuan Capital continued to make additional investment
.
The financing funds will be used for new product research and development, clinical research, registration applications and chip iteration
.
Shinwoo Medical is an independent R&D and production of medical devices in the field of implantable neuroregulation, with the mission of continuously providing doctors and patients with more advanced and effective treatment methods, and is committed to improving the quality of life
of more refractory patients.
It is worth mentioning that in the past year, Shenwoo Medical has completed three rounds of financing
of more than 100 million yuan.
The industry believes that the continuous recognition of professional investment institutions not only shows the great potential of the neuromodulation track, but also verifies the value of
the team and solutions of Novologo.
Changde Medical completes tens of millions of yuan in angel round financing Recently, Shanghai Changde Medical Technology Co.
, Ltd.
(hereinafter referred to as "Changde Medical") completed tens of millions of yuan in angel round financing
.
This round of financing is led by Legend Capital and co-invested by Shanghai Xinyue Jiupeng Enterprise Consulting Center (limited partnership), and the financing amount will be used for the research and development
of the company's peripheral intervention pipeline.
Changde Medical is committed to efficiently creating a complete set of solutions in the field of peripheral interventional devices, and developing drug balloons, catheters, stents, thrombus removal equipment and other products
for peripheral arteriovenous diseases.
At present, Changde Medical has a rich product pipeline, and has also launched a series of research and development projects
such as balloons, stents, catheters for peripheral artery stenosis, varicose veins, deep vein thrombosis and arteriovenous fistula.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.